Hemophilia Clinical Trials in Tianjin, Tianjin Municipality
16 recruitingTianjin, Tianjin Municipality, China
Showing 1–16 of 16 trials
Recruiting
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Hemophilia
Institute of Hematology & Blood Diseases Hospital, China100 enrolled2 locationsNCT06992076
Recruiting
Phase 3
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.40 enrolled18 locationsNCT06922045
Recruiting
Phase 3
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Hemophilia A or B
Suzhou Alphamab Co., Ltd.70 enrolled1 locationNCT07545395
Recruiting
Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Hemophilia AHemophilia B
Pfizer245 enrolled75 locationsNCT05145127
Recruiting
Phase 3
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Hemophilia AHemophilia B
Pfizer100 enrolled66 locationsNCT05611801
Recruiting
Phase 2Phase 3
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
Hemophilia A
Shanghai Xinzhi BioMed Co., Ltd.55 enrolled10 locationsNCT06111638
Recruiting
Phase 4
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
HemophiliaInhibitors
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07406139
Recruiting
National Longitudinal Cohort of Hematological Diseases
Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 3
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
Hemophilia A
Gritgen Therapeutics Co., Ltd.50 enrolled13 locationsNCT06833983
Recruiting
Not Applicable
Gene Therapy for Chinese Hemophilia A
Hemophilia AGene Therapy
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT04728841
Recruiting
Early Phase 1
Safety and Tolerability of VGB-R04 in Patients With Haemophilia B
Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China3 enrolled1 locationNCT05152732
Recruiting
Phase 1
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China9 enrolled1 locationNCT05709288
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT05641610
Recruiting
Not Applicable
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China6 enrolled1 locationNCT05630651
Recruiting
Early Phase 1
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China6 enrolled1 locationNCT06238908
Recruiting
Early Phase 1
A Study of FVIII Gene Therapy for Hemophilia A
Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China8 enrolled1 locationNCT05454774